Among those with adverse-risk AML and TP53 mutations, median OS was 5.0 months with CPX-351 (n = 24) versus 5.1 months with 7 + 3 (n = 31; Additional file 1: Table S1). The gene discussed is TP53; the disease is acute myeloid leukemia.